CGSO National Videoconference: Rectal Cancer (2021)-Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983):

Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983):

Back to course

Pdf Summary

A large, long-term study published in The Lancet Oncology found that perioperative chemotherapy with FOLFOX4 (folinic acid, fluorouracil, and oxaliplatin) does not significantly improve overall survival compared to surgery alone for patients with resectable liver metastases from colorectal cancer. The study involved 364 patients recruited from 78 hospitals across Europe, Australia, and Hong Kong. Patients were randomly assigned to either perioperative FOLFOX4 or surgery alone. Analysis of overall survival showed no significant difference between the two groups. However, the study did find that perioperative chemotherapy with FOLFOX4 increases progression-free survival and should remain the reference treatment for this population of patients. The study was supported by grants from the Norwegian and Swedish Cancer Societies, Cancer Research UK, Ligue Nationale Contre Cancer, US National Cancer Institute, and Sanofi-Aventis. The researchers believe that although the results were not statistically significant, perioperative chemotherapy with FOLFOX4 should remain the reference treatment, and more studies on its effectiveness would be useful.

Keywords

perioperative chemotherapy

FOLFOX4

overall survival

surgery alone

resectable liver metastases

colorectal cancer

progression-free survival

reference treatment

long-term study

The Lancet Oncology